Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPABID trial of pipamperone and aripiprazole for challenging behavior in intellectual disability
NL-OMON60529Phase 4Not yet recruiting
- Sponsor
- GGZ Drenthe
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pipamperone and aripiprazole in intellectual disability (ID) (2 arms), sponsored by GGZ Drenthe. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
pipamperonearipiprazole
03
Conditions
intellectual disability (ID)
Beyond the preview
Go deeper on NL-OMON60529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60529.